Pemphigus Vulgaris

The European Medicines Agency Committee for Medicinal Products for Human Use has recommended the launch of proposed biosimilar rituximab candidate Ituxredi, Dr. Reddy’s Laboratories announced in a press release.

An association with long-term complete remission was found in patients with pemphigus who used rituximab as first-line therapy, according to an extension study.

In patients with pemphigus vulgaris and pemphigus foliaceus, adjuvant immunoadsorption did not lessen the time to clinical remission, according to a study.

Quality of life is impaired with negative psychological health outcomes in patients with immunobullous dermatoses, and systemic corticosteroids may increase these risks, according to a poster presentation.

Rituxan met a primary endpoint and demonstrated it is superior to mycophenolate mofetil in adults with moderate to severe pemphigus vulgaris in the phase 3 PEMPHIX study, which was presented at the European Academy of Dermatology and Venereology Congress.